Nov 26, 2024 8:00am EST Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial
Oct 08, 2024 8:00am EDT Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit
Oct 02, 2024 8:00am EDT Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries
Sep 13, 2024 8:00am EDT Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024
Aug 29, 2024 8:00am EDT Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants